In the context of autoimmunity, MS patients treated with anthelminthic molecules show an increased clinical MS activity correlated with higher IFN-γ and IL-12 expression and a drop in the number of regulatory cells [57]. This evidence concerns the gene IFNG and myeloid sarcoma.